Cognition Therapeutics Q2 EPS $(0.16) Beats $(0.19) Estimate
Portfolio Pulse from sunil@benzinga.com
Cognition Therapeutics (NASDAQ:CGTX) reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.19) by 15.79%. This represents a 36% improvement over losses of $(0.25) per share from the same period last year.
August 08, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cognition Therapeutics' Q2 losses were less than expected, indicating a positive financial performance. This could potentially lead to a short-term increase in the company's stock price.
Cognition Therapeutics reported lower than expected losses for Q2, which is a positive signal for investors. This could lead to increased investor confidence and a potential short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100